Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31402902 | 0.90 | GPR119 (0.52) | GPR119AKR1C3RORC | |
| SCHEMBL12408703 | 0.90 | GPR119 (0.52) | GPR119AKR1C3RORC | |
| SCHEMBL10067757 | 0.87 | RORC (0.48) | GPR119AKR1C3RORCJAK2JAK3 | |
| SCHEMBL6878147 | 0.86 | RORC (0.49) | GPR119RORC | |
| SCHEMBL28849550 | 0.84 | GPR119 (0.60) | GPR119AKR1C3CYP3A4 | |
| SCHEMBL8193760 | 0.83 | KDM4E (0.60) | RORC | |
| SCHEMBL12826096 | 0.80 | LMNA (0.59) | GPR119AKR1C3 | |
| SCHEMBL10395260 | 0.79 | L3MBTL3 (0.69) | GPR119 | |
| Methylene Chloride SCHEMBL28170853 | 0.79 | GPR119 (0.55) | GPR119AKR1C3CYP3A4CTSBCTSS | |
| SCHEMBL7301452 | 0.79 | JAK2 (0.64) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102639500-B | Tricyclic compound, preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-102639500-A | Tricyclic compound, preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2012-08-15 | — | — | CN | disclosed |
| CN-102432598-A | Tricyclic compound, preparation method thereof and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO | 2012-05-02 | — | — | CN | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| CN-101252929-A | G protein-coupled receptor agonists | PROSIDION LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885AKR1C3 1609/4885RORC 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.